Durable Mechanical Circulatory Support versus Organ Transplantation: Past, Present, and Future

Figure 3

Estimated one-year actuarial survival for continuous-flow versus pulsatile flow LVAD therapy—this figure illustrates the one- and two-year actuarial survival for continuous-flow (HeartMate II) and pulsatile-flow (HeartMate XVE) LVADs. The results demonstrate the superiority of continuous-flow support [22].